Trials / Conditions / Platinum-Refractory Fallopian Tube Carcinoma
Platinum-Refractory Fallopian Tube Carcinoma
5 registered clinical trials studyying Platinum-Refractory Fallopian Tube Carcinoma — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Withdrawn | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without B NCT06393751 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent NCT05295589 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Peg NCT05271318 | TILT Biotherapeutics Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents NCT04739800 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With NCT03508570 | M.D. Anderson Cancer Center | Phase 1 |